JP2023510958A5 - - Google Patents
Info
- Publication number
- JP2023510958A5 JP2023510958A5 JP2022544061A JP2022544061A JP2023510958A5 JP 2023510958 A5 JP2023510958 A5 JP 2023510958A5 JP 2022544061 A JP2022544061 A JP 2022544061A JP 2022544061 A JP2022544061 A JP 2022544061A JP 2023510958 A5 JP2023510958 A5 JP 2023510958A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding molecule
- immune cell
- immune
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025154666A JP2026001027A (ja) | 2020-01-22 | 2025-09-18 | 操作された免疫細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2000934.6A GB202000934D0 (en) | 2020-01-22 | 2020-01-22 | Engineered immune cells |
| GB2000934.6 | 2020-01-22 | ||
| PCT/GB2021/050128 WO2021148788A1 (en) | 2020-01-22 | 2021-01-21 | Engineered immune cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154666A Division JP2026001027A (ja) | 2020-01-22 | 2025-09-18 | 操作された免疫細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023510958A JP2023510958A (ja) | 2023-03-15 |
| JP2023510958A5 true JP2023510958A5 (enExample) | 2024-01-24 |
Family
ID=69636913
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544061A Pending JP2023510958A (ja) | 2020-01-22 | 2021-01-21 | 操作された免疫細胞 |
| JP2025154666A Pending JP2026001027A (ja) | 2020-01-22 | 2025-09-18 | 操作された免疫細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154666A Pending JP2026001027A (ja) | 2020-01-22 | 2025-09-18 | 操作された免疫細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230049025A1 (enExample) |
| EP (1) | EP4093431A1 (enExample) |
| JP (2) | JP2023510958A (enExample) |
| CN (1) | CN115315270A (enExample) |
| AU (1) | AU2021211185A1 (enExample) |
| CA (1) | CA3165473A1 (enExample) |
| GB (1) | GB202000934D0 (enExample) |
| WO (1) | WO2021148788A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230227575A1 (en) * | 2022-01-10 | 2023-07-20 | Expression Therapeutics, Llc | Engineered T Cells |
| GB202204272D0 (en) * | 2022-03-25 | 2022-05-11 | Ucl Business Ltd | Method for engineering innate-like lymphocytes |
| EP4622715A1 (en) * | 2022-11-22 | 2025-10-01 | Expression Therapeutics, LLC | Engineered t cells |
| EP4648854A1 (en) * | 2023-01-10 | 2025-11-19 | Expression Therapeutics, LLC | Engineered t cells |
| GB202416012D0 (en) * | 2024-10-30 | 2024-12-11 | Ucl Business Ltd | Engineered immune cells |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| EP1916257A1 (en) * | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| US11352439B2 (en) * | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
| CN107523545A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的杀伤性细胞及其用途 |
| US20190307799A1 (en) * | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
| WO2018118494A2 (en) * | 2016-12-22 | 2018-06-28 | Xiaotong Song | Use of car-modified human natural killer cells to treat cancer |
| EP3600357A4 (en) * | 2017-03-31 | 2021-01-06 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING |
| EP3621988A1 (en) * | 2017-05-09 | 2020-03-18 | Bellicum Pharmaceuticals, Inc. | Methods to augment or alter signal transduction |
| EP3508499A1 (en) * | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
| WO2020021045A2 (en) * | 2018-07-26 | 2020-01-30 | Ospedale Pediatrico Bambino Gesù (Opbg) | Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use |
-
2020
- 2020-01-22 GB GBGB2000934.6A patent/GB202000934D0/en not_active Ceased
-
2021
- 2021-01-21 JP JP2022544061A patent/JP2023510958A/ja active Pending
- 2021-01-21 EP EP21701588.2A patent/EP4093431A1/en active Pending
- 2021-01-21 WO PCT/GB2021/050128 patent/WO2021148788A1/en not_active Ceased
- 2021-01-21 CN CN202180022834.0A patent/CN115315270A/zh active Pending
- 2021-01-21 CA CA3165473A patent/CA3165473A1/en active Pending
- 2021-01-21 US US17/759,222 patent/US20230049025A1/en active Pending
- 2021-01-21 AU AU2021211185A patent/AU2021211185A1/en active Pending
-
2025
- 2025-09-18 JP JP2025154666A patent/JP2026001027A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12233090B2 (en) | Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19 | |
| US11530264B2 (en) | Multifunctional protein | |
| EP4182447A1 (en) | Pseudotyped viruses configured to express car in t-cells | |
| JP2022548796A5 (enExample) | ||
| JP2023501722A5 (enExample) | ||
| US20250304690A1 (en) | Therapeutic agent comprising multispecific antibody and use thereof in tumor therapy | |
| CA2903096A1 (en) | Oncolytic virus | |
| JP2026001027A (ja) | 操作された免疫細胞 | |
| KR20180083868A (ko) | 종양 형질도입용 조성물 및 방법 | |
| JP2023525720A5 (enExample) | ||
| IL297514A (en) | Vectors and methods for in vivo transduction | |
| JP2022531577A5 (enExample) | ||
| JP2022516710A5 (enExample) | ||
| WO2020092839A1 (en) | Methods and materials for treating cancer | |
| KR20260010705A (ko) | 바이러스 및 바이러스 유사 입자의 정제 | |
| RU2707535C2 (ru) | Генетическая конструкция, кодирующая структуру т-клеточного химерного рецептора на основе одноцепочечных vhh-антител, специфичных опухолевому рецептору cd47, для нацеленной иммунотерапии злокачественных новообразований | |
| WO2025098508A1 (zh) | 标记性多肽、治疗剂及其应用 | |
| CN121006385A (zh) | 一种修饰的病毒载体及其制备方法与应用 | |
| Orentas et al. | ALK (anaplastic lymphoma kinase, CD246)-specific CARs: new immunotherapeutic agents for the treatment of pediatric solid tumors |